Quick Answer
Spero Therapeutics, Inc. reported Cash and Equivalents of $40.27 million for fiscal year 2025.
Spero Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $40.27M | -23.9% |
| 2024 | $52.89M | -30.7% |
| 2023 | $76.33M | -30.0% |
| 2022 | $109.11M | -3.1% |
| 2021 | $112.58M | +32.1% |
| 2020 | $85.21M | +186.6% |
| 2019 | $29.73M | -12.8% |
| 2018 | $34.08M | -61.0% |
| 2017 | $87.29M | +746.2% |
| 2016 | $10.31M | +81.3% |
| 2015 | $5.69M | +2123.0% |
| 2014 | $256.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $48.62M | -36.3% | +55.9% |
| June 30, 2025 | $31.19M | -50.9% | -36.2% |
| March 31, 2025 | $48.89M | -40.6% | -7.6% |
| December 31, 2024 | $52.89M | -30.7% | -30.7% |
| September 30, 2024 | $76.29M | -18.7% | +20.1% |
| June 30, 2024 | $63.53M | -18.2% | -22.8% |
| March 31, 2024 | $82.27M | -14.5% | +7.8% |
| December 31, 2023 | $76.33M | -30.0% | -18.6% |
- Spero Therapeutics, Inc. showed a decrease of -23.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2025 period, Spero Therapeutics, Inc.’s cash and equivalents has grown by 15628.5% (from $256.0 thousand to $40.27 million).
- The most recent figure is from Spero Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: